このページの翻訳は実験的なもので、現在開発中です。お待ちしております
ACADIA Pharmaceuticals 将来の成長
Future 基準チェック /56
ACADIA Pharmaceuticals利益と収益がそれぞれ年間41.8%と12.2%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に28.4% 40.9%なると予測されています。
主要情報
41.7%
収益成長率
40.3%
EPS成長率
Biotechs 収益成長 | 28.4% |
収益成長率 | 10.5% |
将来の株主資本利益率 | 30.9% |
アナリストカバレッジ | Good |
最終更新日 | 13 Aug 2024 |
今後の成長に関する最新情報
ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Recent updates
Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
Aug 26The Strong Earnings Posted By ACADIA Pharmaceuticals (NASDAQ:ACAD) Are A Good Indication Of The Strength Of The Business
Aug 14ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Aug 01Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being
May 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Apr 24We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Mar 27Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue
Mar 12ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing
Feb 29Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
Jan 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Jan 03We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Dec 04Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price
May 22Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah
Oct 19FDA accepts Acadia's new drug application for Rett syndrome treatment trofinetide
Sep 12Acadia: Powerful Unfolding Catalysts
Aug 03Acadia Pharma submits marketing application to FDA for trofinetide to treat Rett syndrome
Jul 18FDA AdComm Rejects Nuplazid This Time But Acadia's Race Isn't Run Yet
Jun 29Companies Like ACADIA Pharmaceuticals (NASDAQ:ACAD) Can Afford To Invest In Growth
May 07業績と収益の成長予測
日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
---|---|---|---|---|---|
12/31/2026 | 1,180 | 277 | 290 | 445 | 15 |
12/31/2025 | 1,061 | 156 | 143 | 225 | 19 |
12/31/2024 | 952 | 88 | 138 | 261 | 19 |
6/30/2024 | 891 | 31 | 80 | 81 | N/A |
3/31/2024 | 814 | -2 | 24 | 64 | N/A |
12/31/2023 | 726 | -61 | -23 | 17 | N/A |
9/30/2023 | 632 | -149 | -133 | -93 | N/A |
6/30/2023 | 551 | -111 | -74 | -34 | N/A |
3/31/2023 | 520 | -146 | -56 | -56 | N/A |
12/31/2022 | 517 | -216 | -114 | -114 | N/A |
9/30/2022 | 512 | -217 | -113 | -113 | N/A |
6/30/2022 | 512 | -205 | -130 | -130 | N/A |
3/31/2022 | 493 | -214 | -142 | -142 | N/A |
12/31/2021 | 484 | -168 | -127 | -126 | N/A |
9/30/2021 | 474 | -192 | -133 | -130 | N/A |
6/30/2021 | 463 | -262 | -141 | -136 | N/A |
3/31/2021 | 458 | -260 | -155 | -147 | N/A |
12/31/2020 | 442 | -282 | -144 | -136 | N/A |
9/30/2020 | 419 | -268 | -144 | -138 | N/A |
6/30/2020 | 393 | -225 | -139 | -134 | N/A |
3/31/2020 | 366 | -238 | -137 | -136 | N/A |
12/31/2019 | 339 | -235 | -152 | -151 | N/A |
9/30/2019 | 300 | -248 | -162 | -161 | N/A |
6/30/2019 | 264 | -268 | -186 | -184 | N/A |
3/31/2019 | 238 | -276 | -189 | -186 | N/A |
12/31/2018 | 224 | -245 | -170 | -167 | N/A |
9/30/2018 | 208 | -249 | -160 | -158 | N/A |
6/30/2018 | 185 | -252 | -175 | -174 | N/A |
3/31/2018 | 158 | -256 | N/A | -192 | N/A |
12/31/2017 | 125 | -289 | N/A | -218 | N/A |
9/30/2017 | 93 | -299 | N/A | -251 | N/A |
6/30/2017 | 63 | -306 | N/A | -242 | N/A |
3/31/2017 | 33 | -309 | N/A | -240 | N/A |
12/31/2016 | 17 | -271 | N/A | -208 | N/A |
9/30/2016 | 5 | -238 | N/A | -182 | N/A |
6/30/2016 | 0 | -206 | N/A | -165 | N/A |
3/31/2016 | 0 | -174 | N/A | -138 | N/A |
12/31/2015 | 0 | -164 | N/A | -122 | N/A |
9/30/2015 | 0 | -147 | N/A | -105 | N/A |
6/30/2015 | 0 | -133 | N/A | -91 | N/A |
3/31/2015 | 0 | -115 | N/A | -78 | N/A |
12/31/2014 | 0 | -92 | N/A | -66 | N/A |
9/30/2014 | 0 | -76 | N/A | -59 | N/A |
6/30/2014 | 0 | -62 | N/A | -51 | N/A |
3/31/2014 | 1 | -50 | N/A | -39 | N/A |
12/31/2013 | 1 | -38 | N/A | -32 | N/A |
9/30/2013 | 1 | -33 | N/A | -28 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: ACADの予測収益成長率 (年間40.8% ) は 貯蓄率 ( 2.5% ) を上回っています。
収益対市場: ACADの収益 ( 40.8% ) はUS市場 ( 14.9% ) よりも速いペースで成長すると予測されています。
高成長収益: ACADの収益は今後 3 年間で 大幅に 増加すると予想されています。
収益対市場: ACADの収益 ( 12.2% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。
高い収益成長: ACADの収益 ( 12.2% ) 20%よりも低い成長が予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: ACADの 自己資本利益率 は、3年後には高くなると予測されています ( 28.4 %)